Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
84 participants
OBSERVATIONAL
2023-08-10
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study
NCT05855460
Resident Memory T Cells in Vitiligo
NCT05223738
Sensory Symptoms in Active Vitiligo
NCT05390164
Thymic Stromal Lymphopoietin (TSLP) in Vitiligo
NCT03367273
Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo
NCT05812079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active vitiligo
IL 35 in tissue biopsy
Elisa testing
Stable vitiligo
IL 35 in tissue biopsy
Elisa testing
Normal controls
IL 35 in tissue biopsy
Elisa testing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IL 35 in tissue biopsy
Elisa testing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with associated autoimmune or other dermatological diseases e.g., Alopecia areata and lupus erythematous.
* Patients already on both topical and systemic treatment at the time of recruitment.
* Patients on Immunosuppressive drugs.
* Other hypopigmented diseases such as pityriasis alba, tinea versicolor, lichen sclerosis, post inflammatory hypopigmentation and leprosy as excluded by lack of accentuation by wood's light examination.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hagar El Sayed
Dr
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IL35 in vitiligo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.